Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes
Clinical trial NCT05950516 · UNKNOWN
Trial details
- NCT number
- NCT05950516
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-10
- Primary completion
- 2024-11-24
- Enrollment
- 478
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.